Takeda Pharmaceutical Co. Ltd.

Company Overview

Takeda Pharmaceutical Co., Ltd. focuses on metabolic disorders, gastroenterology, neurology, inflammation, and oncology. Takeda entered the U.S. pharmaceutical market by forming a joint venture with Abbott Laboratories, known as TAP Pharmaceuticals. In 2011, the company acquired Nycomed A/S.

Takeda Pharmaceutical Co. business is organized into a single operating segment, It is a holding company that manages operations through several global subsidiaries.

Millennium Pharmaceuticals (a wholly owned subsidiary of Takeda Pharmaceutical) co-developed Velcade with Janssen Pharmaceutical (a part of Johnson & Johnson). Takeda and Ortho Biotech are jointly marketing Velcade in the United States for a limited time. Takeda Pharmaceutical Co. Ltd. and Janssen Pharmaceutical are co-promoting Velcade in Japan, with Janssen Pharmaceutical responsible for its commercialization in Europe and worldwide.

Financial Highlights (FY 2024)

Company's Business Segments

• Gastroenterology (GI) : Ulcerative colitis or Crohn’s disease, Refractory complex perianal fistulas.
• Rare Diseases : Prevention of hereditary angioedema attacks, Post-transplant CMV infection.
• PDT immunology : Primary and secondary immunodeficiencies and multifocal motor neuropathy, Hypovolemia, hypoalbuminemia.
• Oncology : ALK-positive non-small cell lung cancer
• Others : Dengue diseas, Active immunization, COVID-19 and others